Source: DGNews | Posted 8 years ago
New Data on Abraxane Demonstrate Almost Double the Response Rate versus Taxol in Patients With Metastatic Breast Cancer
Tags:
A Promising New Direction Emerges for One of the Most Widely Used Chemotherapies in the World, Paclitaxel
CHICAGO, IL - December 15, 2003 - Results of a Phase III head-to-head trial of the investigational drug Abraxane, the first solvent-free nanoparticle taxane, versus the solvent-based Taxol
Comments